Association between Comorbidities and Progression of Transvalvular Pressure Gradients in Patients with Moderate and Severe Aortic Valve Stenosis

Table 2

Comorbidities of patients with slow or fast progression of mean transaortic pressure gradient at baseline and follow-up echocardiography.

	Total cohort		Slow progression (Pmean < 5 mmHg/year)		Fast Progression (Pmean ≥ 5 mmHg/year)		value
		%		%		%
Sex							0.98
Male	233	58.0	152	58.0	81	57.9
Female	169	42.0	110	42.0	59	42.1
Comorbidities at baseline
BMI≥30 Kg/m^2	89	29.4	55	28.1	34	31.8	0.51
History of smoking	146	36.3	96	36.6	50	35.7	0.91
Diabetes	144	35.8	101	38.5	43	30.7	0.13
Coronary heart disease	176	43.8	129	49.2	47	33.6	0.003
Myocardial infarction	88	21.9	67	25.6	21	15.0	0.016
Hypertension	350	87.1	230	87.8	120	85.7	0.64
Renal dysfunction	210	53.3	146	56.6	64	47.1	0.09
Peripheral artery occlusive disease	93	23.1	68	26	25	17.9	0.08
Cerebrovascular disease	59	14.7	34	13	25	17.9	0.24
Comorbidities at follow-up
BMI≥30 Kg/m^2	145	38.7	96	39.3	49	37.4	0.70
History of smoking	147	36.6	97	37	50	35.7	0.80
Diabetes	161	40.0	115	43.9	46	32.9	0.033
Coronary heart disease	228	56.9	159	60.9	69	49.3	0.027
Myocardial infarction	104	25.9	81	30.9	23	16.4	0.002
Hypertension	368	91.5	239	91.2	129	92.1	0.85
Renal dysfunction	281	69.9	188	71.8	93	66.4	0.30
Peripheral artery occlusive disease	141	35.1	93	35.5	48	34.3	0.83
Cerebrovascular disease	79	19.7	44	16.8	35	25.0	0.06
History of statin-therapy	244	65.4	149	61.1	71	55.0	0.27

BMI, body mass index; P_mean, mean transaortic pressure gradient.